Physiomics plc (AIM: PYC) has secured new contracts worth more than £205,000, extending a strong run of commercial wins for the mathematical modelling, data science and biostatistics specialist.
Physiomics plc (AIM: PYC) Director Dealing
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the
Physiomics (AIM: PYC) Awarded Multiple New Contracts
Physiomics plc (AIM: PYC) has secured multiple new contract awards with a combined estimated value of more than £200,000.
Physiomics plc (AIM: PYC) Appointment of Chief Operating Officer
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the promotion of
Physiomics strengthens outlook with cost savings and pipeline growth
Physiomics (AIM: PYC) has provided a positive operational update, highlighting record commercial opportunities, cost savings and a clearer path towards profitability as the AIM-listed modelling and data science specialist executes
Why Physiomics Could Be Entering A New Phase Of Commercial Growth
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing
Physiomics Demonstrates Hantavirus Translational Modelling Capability
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to highlight the development of
Physiomics plc (AIM: PYC) Awarded Multiple New Contracts
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far
Why Physiomics Could Be Entering A New Phase Of Commercial Growth
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing
Physiomics plc (AIM: PYC) Update regarding CEO – Peter Sargent
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that Peter Sargent
Why Physiomics Could Be Entering A New Phase Of Commercial Growth
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing
Physiomics PLC (PYC.L) Conference presentation
Physiomics to present on Personalized Medicine and Virtual Tumour at AACR 2021 Annual Meeting